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OBJECTIVE: To analyze the preoperative plasma antigenic concentration and activity of von Willebrand factor
and its main cleaving protease ADAMTS-13 in pediatric patients with cyanotic congenital heart disease
undergoing surgical treatment and investigate possible correlations with postoperative bleeding.
METHODS: Plasma antigenic concentrations (von Willebrand factor:Ag and ADAMTS-13:Ag) were measured
using enzyme-linked immunoassays. Collagen-binding assays were developed to measure biological activities
(von Willebrand factor:collagen binding and ADAMTS-13 activity). The multimeric structure of von Willebrand
factor was analyzed using Western immunoblotting. Demographic, diagnostic, and general and specific
laboratory data and surgery-related variables were subjected to univariate, bivariate, and multivariate analysis
for the prediction of postoperative bleeding.
RESULTS: Forty-eight patients were enrolled, with ages ranging from 9 months to 7.6 years (median 2.5 years).
The plasma concentrations of von Willebrand factor:Ag and ADAMTS-13:Ag were decreased by 65 and 82%,
respectively, in the patients compared with the controls (p,0.001). An increased density of low-molecular-weight
fractions of von Willebrand factor, which are suggestive of proteolytic degradation (p= 0.0081), was associated
with decreased ADAMTS-13 activity, which was likely due to ADAMTS-13 consumption (71% of controls,
p= 0.0029) and decreased von Willebrand factor:collagen binding (76% of controls, p= 0.0004). Significant
postoperative bleeding occurred in 13 patients. The preoperative ADAMTS-13 activity of,64.6% (mean level for
the group), preoperative activated partial thromboplastin time, and the need for cardiopulmonary bypass were
characterized as independent risk factors for postoperative bleeding, with respective hazard ratios of 22.35 (95%
CI 1.69 to 294.79), 1.096 (95% CI 1.016 to 1.183), and 37.43 (95% CI 1.79 to 782.73).
CONCLUSION: Low plasma ADAMTS-13 activity is a risk factor for postoperative bleeding in children with cyanotic
congenital heart disease, particularly in children undergoing cardiopulmonary bypass.
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& INTRODUCTION
ADAMTS-13 (a desintegrin and metalloprotease with throm-
bospondin type 1 motif) is a member of a family of zinc
metalloproteases and is primarily synthesized in hepatic
stellate cells (1), although other sources have been identi-
fied. The principal function of ADAMTS-13 is the physio-
logical (limited) cleavage of von Willebrand factor (VWF).
Mutations of the ADAMTS-13 gene are associated with the
presence of extra-large VWF multimers in plasma, which is
the molecular basis of congenital thrombotic thrombocyto-
penic purpura (2). Abnormal circulating levels of VWF and
ADAMTS-13 have been reported in numerous acquired
disorders, including cardiovascular diseases (3,4). Increased
plasma VWF antigen (VWF:Ag) and/or decreased
ADAMTS-13 activity are generally associated with poor
outcomes in these conditions (5,6).
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Changes in ADAMTS-13 activity and VWF have been
reported in patients undergoing cardiac surgery (7) but
have not been investigated in the pediatric population. In
patients with cyanotic congenital heart disease (CCHD),
abnormalities in coagulation parameters and platelet func-
tion are common. These abnormalities tend to be more
pronounced in the perioperative period, particularly in
subjects undergoing cardiopulmonary bypass (8-10). We
designed the present study to investigate preoperative
abnormalities in circulating ADAMTS-13 and VWF in
children with CCHD and possible correlations with post-
operative bleeding.
& METHODS
Patients and general data recorded
Pediatric patients with CCHD from the Department of
Pediatric Cardiology and Adult Congenital Heart Disease,
Heart Institute, Faculdade Medicina da Universidade de Sa˜o
Paulo, Sa˜o Paulo, Brazil, were evaluated preoperatively on a
hospital basis and consecutively included in the study (first
operation or reoperation). Neonates, patients under inten-
sive care, and patients undergoing emergency cardiac
surgery were not included. Recorded parameters included
demographics and general laboratory data, the principal
diagnosis (as established by Doppler-echocardiography
and, in some cases, angiography), the type of surgery, the
need for cardiopulmonary bypass and its duration, and
relevant postoperative events (e.g., infection, sepsis, bleed-
ing, and death). Relevant postoperative bleeding was
defined as 10 mL/Kg/hour during the first hour and
5 mL/Kg/hour after the first hour, requiring a blood
transfusion. The study protocol was approved by the
Scientific and Ethics Committee of the Heart Institute and
the Hospital das Clinicas da Faculdade de Medicina da
Universidade de Sa˜o Paulo, CAPPESq #7106. Written
informed consent was required for patient inclusion.
Biochemical determinations
One day before the surgery, peripheral venous blood was
collected in 1:10 volumes 3.2% sodium citrate for analysis of
plasma VWF:Ag, VWF biological activity (VWF:CB),
ADAMTS-13 antigenic concentration (ADAMTS-13:Ag),
and ADAMTS-13 activity. Protease inhibitors were added
to analyze the VWF multimeric composition (11). Plasma
VWF:Ag and ADAMTS-13:Ag were determined using
enzyme-linked immunosorbent assays (Diagnostica Stago,
Asnie`res, France, and Technoclone, Vienna, Austria, respec-
tively). The results were expressed as U/dL and mg/mL,
respectively. Plasma VWF:CB was interpreted as the ability
of VWF to bind to collagen (12). An in-house enzyme
immunoassay was developed using a peroxidase-conjugated
rabbit antihuman VWF polyclonal antibody (Dako
Corporation, Carpinteria, CA, USA). The results were
expressed as percent activity. The ADAMTS-13 activity was
determined using a previously described collagen-binding
assay (13). Briefly, diluted plasma samples were added to
plate wells precoated with collagen (Vitrogen, Cohesion
Corp., Palo Alto, CA, USA) with or without previous dialysis
against 1.5 M urea. The binding of VWF to collagen was
measured using a peroxidase-labeled rabbit antihuman VWF
antibody (Dako Corporation). The ADAMTS-13 activity
calculation compared the VWF binding after dialysis
(residual) with the binding in the sample not subjected to
dialysis. The results were expressed as percent activity.
Proteolysis of VWF multimers was analyzed using Western
immunoblotting as previously described (11). The results
were expressed as the density of VWF low-molecular-weight
fractions relative to the density of all the fractions (laser
densitometry). In all the determinations, the results were
compared with a control group of nine healthy children
within the same age range.
Statistical analysis
The results are presented as the mean and standard
deviation or median and range. Comparisons between
groups were performed using the Student’s t-test, Mann-
Whitney test, or Kruskal-Wallis test. The association
between numeric variables was tested using linear regres-
sion and correlation. Logistic regression models were
constructed to investigate possible predictors of postopera-
tive bleeding. Once a variable was selected as a potential
candidate based on univariate analysis, bivariate analysis
was used to test for possible confounders. A confounder
was defined as a second variable causing a significant
reduction in the hazard ratio associated with the variable
under investigation. Multivariate analysis was conducted
by including all the variables with a p-value of ,0.10 in the
univariate and bivariate analyses. A reduced multivariate
model was developed using only the variables with a p-
value of ,0.10 in the first step of the multivariate analysis.
In the final analyses, 0.05 was adopted as the significance
level.
& RESULTS
Demographics, diagnosis, and general laboratory
data
The study group consisted of 48 pediatric patients (24
males, aged 9 months to 7.6 years, median age 2.5 years,
body weight 11.9¡3.7 Kg) with tetralogy of Fallot (N=11),
pulmonary atresia with a ventricular septal defect (N= 14),
or a univentricular heart (N= 23). Patients exhibited
decreased systemic oxygen saturation compared with the
controls (median 80% (range: 53 to 91%) and median 98%
(range: 95 to 99%), respectively, p,0.0001), increased
hematocrit levels (47¡7 and 37¡3%, respectively,
p,0.0001), increased hemoglobin levels (15.9¡2.3 and
12.7¡1.2 g/dL, respectively, p,0.0001), and normal platelet
counts (313¡1146109 and 301¡566109 platelets/L, respec-
tively, p=NS). Blood coagulation test results were within
the normal range (activated partial thromboplastin time
(APTT) normalized ratio of 1.11¡0.13 and prothrombin
time international normalized ratio of 1.12¡0.11).
Specific laboratory determinations
The preoperative VWF:Ag levels were decreased in the
patients (Table 1) compared with the controls; the lowest
levels were observed in subjects with pulmonary atresia,
followed by those with tetralogy of Fallot and a univen-
tricular heart (69, 73, and 85 U/dL, respectively, p= 0.0072).
A proteolytic pattern of VWF protein (multimers) was
observed (Table 1 and Figure 1), which was associated with
decreased VWF:CB and decreased ADAMTS-13 (both
antigen and activity, which was likely due to enzyme
consumption) (Table 1). The lowest levels of VWF:CB were
observed in subjects with the lowest levels of ADAMTS-13
activity (r = 0.60, p,0.0001, Figure 2). The ratio of VWF:Ag/
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ADAMTS-13 activity did not change because both values
were reduced. Except for VWF:Ag, no differences were
detected between the diagnostic groups. The only associa-
tion with general laboratory parameters was a positive
correlation between the ADAMTS-13:Ag and the systemic
oxygen saturation (r = 0.44, p= 0.002).
Surgery and immediate outcomes
The patients were subjected to total repair of tetralogy of
Fallot (N= 11) or pulmonary atresia (N= 7), Glenn- (N= 14)
or Fontan-type (N= 9) cavopulmonary connection, modified
Blalock-Taussig anastomosis (N= 6), or pulmonary artery
banding (N=1). Cardiopulmonary bypass was required in
31 instances (duration of 38 to 250 minutes). Three
immediate postoperative deaths associated with low cardiac
output and circulatory collapse occurred. Significant
postoperative bleeding, as previously defined, occurred in
13 patients. Systemic infection or sepsis did not occur in any
of the patients.
Predictors of postoperative bleeding
Preoperative clinical and laboratory parameters, includ-
ing VWF and ADAMTS-13 determinations, were tested for
possible relationships with postoperative bleeding. Of the
specific biochemical markers, low ADAMTS-13 activity was
the only parameter exhibiting a significant association in the
univariate analysis. An activity of ,64.6% (mean (default)
level in the patient group) was associated with a hazard
ratio of 11.33 (95% CI 1.33 to 96.81). The bivariate analysis
results presented in Table 2 showed that the only potential
confounder was VWF:Ag. However, a specific association of
VWF:Ag with bleeding could not be demonstrated (uni-
variate and bivariate analyses). Of the other clinical and
laboratory parameters, preoperative APTT and cardiopul-
monary bypass were also associated with postoperative
bleeding, with p,0.05 in the univariate analysis (Table 2,
variables tested individually).
According to previously established criteria, eight vari-
ables were tested using multivariate analysis (Table 2). The
final reduced multivariate model included three predictors
Table 1 - Preoperative plasma von Willebrand factor and ADAMTS-13.
Patients Controls p-value
VWF:Ag (U/dL) 73 (51-159) 113 (105-129) ,0.0001
VWF:CB (%) 48¡21 63¡9 0.0004
ADAMTS-13:Ag (mg/mL) 0.91¡0.29 1.11¡0.09 0.0002
ADAMTS-13 activity (%) 65¡24 91¡24 0.0029
VWF:Ag/ADAMTS-13 activity 1.17 (0.62-4.84) 1.13 (1.1-1.69) 0.7427
VWF multimers 0.44 (0.11-0.56) 0.36 (0.25-0.55) 0.0081
ADAMTS-13:Ag, plasma ADAMTS-13 antigenic concentration; VWF:Ag, plasma von Willebrand factor antigenic concentration; VWF:Ag/ADAMTS-13
activity, ratio of von Willebrand factor antigenic concentration to ADAMTS-13 activity; VWF:CB, plasma von Willebrand factor activity expressed as
collagen-binding capacity; VWF multimers, ratio of low-molecular-weight multimer density to total multimer density of von Willebrand factor.
Figure 1 - Western immunoblotting of the plasma von
Willebrand factor multimeric structure. Compared with the
controls, children with cyanotic congenital heart diseases
exhibited decreased densities of high-molecular-weight (HMW)
multimers and increased concentrations of low-molecular-
weight (LMW) fractions (5 bands migrating above the IgM
position, 950 kDa), which indicates abnormal proteolytic degra-
dation. This pattern was observed in 36 of the 48 patients
(p= 0.0081, densitometric analysis shown in Table 1).
Figure 2 - Correlation of von Willebrand factor biological activity
(VWF:CB) with ADAMTS-13 activity in children with cyanotic
congenital heart disease. The dashed lines correspond to mean
values in the controls. The lowest levels of ADAMTS-13 activity
correlated with the lowest levels of VWF:CB, which indicates the
involvement of enzyme consumption in the degradation of
biologically active (high-molecular-weight) von Willebrand fac-
tor multimers.
CLINICS 2013;68(4):531-536 ADAMTS-13 in Congenital Heart Disease
Soares RP et al.
533
of postoperative bleeding, including low preoperative
ADAMTS-13 activity (hazard ratio of 22.35 in the final
model, 95% CI 1.69 to 294.79), preoperative APTT (hazard
ratio associated with an increase of 0.01 in the normalized
ratio of 1.096, 95% CI 1.016 to 1.183), and the need for
cardiopulmonary bypass (hazard ratio 37.43, 95% CI 1.79 to
782.73). There were no significant associations among the
three variables. Significant postoperative bleeding occurred
in 40% of the patients with low preoperative ADAMTS-13
activity (versus 6% in the subjects with an ADAMTS-13
activity above the mean/default level, p,0.02), 39% of the
patients undergoing ON-pump surgery (versus 6% of the
patients who were operated on OFF-pump, p,0.02), and
55% of the patients with both risk factors (versus 7% of the
patients with one or no risk factors, p,0.002). The proposed
model was used to estimate the likelihood of bleeding:
P~
EXP {16:67z3:62x1z3:11x2z9:15x3ð Þ
1zEXP {16:67z3:62x1z3:11x2z9:15x3ð Þ where:
P = probability of postoperative bleeding
x1 = 0 or 1 for the absence or presence, respectively, of
cardiopulmonary bypass
x2 = 0 or 1 for the absence or presence, respectively, of
ADAMTS-13 activity ,64.6%
x3 = activated partial thromboplastin time (normalized
ratio)
In the three patients who died postoperatively, the
preoperative biochemical parameters were within the range
of those in the remaining patients, and the structure of the
VWF protein was similar to the structure shown in Figure 1.
& DISCUSSION
The response of endothelial cells to injury involves the
release of numerous substances, including VWF. Increased
circulating levels of VWF are observed, particularly in acute
disorders (5,6), and VWF is considered to be an acute-phase
reactant. Several stimuli and conditions have been shown to
induce the release of VWF from endothelial Weibel-Palade
bodies, including hypoxia, epinephrine, thrombin, fibrin,
cytokines, endotoxin, components of the complement system,
and reactive oxygen intermediates (14-18). ADAMTS-13
activity should theoretically increase in response to the
evaluation of plasma VWF, but in practice, the enzyme
activity varies considerably (19). In conditions associated
with a marked elevation of plasma VWF:Ag (for example,
generalized systemic inflammation), the ADAMTS-13 activ-
ity decreases. The decreased activity is likely due to
consumption of the enzyme, which is associated with an
increase in the VWF:Ag/ADAMTS-13 activity ratio and is a
risk factor for complications. In these instances (enzyme
depletion), extra-large VWF multimers are detected in
circulation (6), which may be associated with a generalized
tendency toward thrombosis and coagulopathy.
Overt endothelial cell activation was not likely in our
relatively stable patients with chronic CCHD, and the
plasma VWF:Ag ratio was not elevated. However, an
ongoing process of abnormal VWF proteolytic degradation
may have been associated with the increased density of low-
molecular-weight VWF species (multimeric analysis) and
decreased VWF antigen and activity. Decreased ADAMTS-
13 activity could be explained by consumption, although
Table 2 - Bivariate analysis of preoperative ADAMTS-13 activity as a predictor of postoperative bleeding.
95% CI for the ADAMTS-13
Second variable
Number of Hazard
hazard ratio Activity In the model Singly
patients ratio (*) Lower Upper p-value p-value p-value
Unadjusted (univariate analysis) 48 11.33 1.33 96.81 0.0265 ({)
Adjusted (bivariate analysis)
Patient age 48 12.38 1.38 111.14 0.0246 0.0616 0.0587 ({)
Body weight 48 12.77 1.44 113.63 0.0223 0.0717 0.0818 ({)
Type of anomaly 48 12.08 1.38 105.96 0.0245 0.6762 0.9195
Oxygen saturation 48 11.90 1.38 102.82 0.0244 0.4810 0.6124
Hemoglobin 48 15.27 1.58 147.35 0.0184 0.2017 0.5086
Platelet count 48 14.85 1.59 138.77 0.0180 0.0627 0.0963 ({)
Leukocyte count 48 18.72 1.88 186.79 0.0126 0.0342 0.0588 ({)
PT (INR) 48 11.64 1.32 102.27 0.0269 0.0895 0.0745 ({)
APTT 48 10.06 1.11 91.25 0.0402 0.0526 0.0228 ({)
VWF:Ag 48 7.73 0.85 70.63 0.0701 0.3115 0.0748
VWF:CB 48 9.96 1.08 91.68 0.0424 0.6873 0.1818
VWF multimers 48 11.41 1.31 99.43 0.0275 0.3280 0.3000
ADAMTS-13:Ag 48 15.58 1.63 148.90 0.0171 0.0814 0.1733
VWF:Ag/ADAMTS-13 activity 48 13.85 1.50 128.16 0.0206 0.5048 0.8113
CBP 48 13.15 1.44 119.86 0.0223 0.0289 0.0346 ({)
CPB time 31 11.84 1.23 114.40 0.0326 0.3727 0.2658
Reoperation ({) 48 12.73 1.44 112.64 0.0222 0.0963 0.1231
ADAMTS-13:Ag, plasma ADAMTS-13 antigenic concentration; APTT, activated partial thromboplastin time expressed as a normalized ratio; CPB,
cardiopulmonary bypass; PT, prothrombin time expressed as the international normalized ratio (INR); VWF:Ag, plasma von Willebrand factor antigenic
concentration; VWF:Ag/ADAMTS-13 activity, ratio of von Willebrand factor antigenic concentration to ADAMTS-13 activity; VWF:CB, plasma von
Willebrand factor activity expressed as collagen-binding capacity; VWF multimers, ratio of low-molecular-weight multimer density to total multimer
density of von Willebrand factor
(*) Associated with a preoperative ADAMTS-13 activity below the default (mean) level of 64.6%.
({) Existing cardiac surgery prior to the current surgery.
({) All variables with a p-value of ,0.10 are indicated on the right in both univariate and bivariate analyses; these variables were tested using the
multivariate model.
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altered enzyme synthesis and/or abnormal degradation
cannot be excluded. ADAMTS-13:Ag values correlated
directly with systemic oxygen saturation in the study.
The hypothesis that chronic proteolysis of VWF accounts
for ADAMTS-13 consumption in children with CCHD is
plausible because altered flow conditions (present in nearly
all of the included anomalies) have been shown to facilitate
the binding of VWF to platelet membrane glycoproteins
(particularly glycoprotein Ib), followed by enzymatic
degradation (20,21). This mechanism has been proposed to
explain the abnormalities in circulating VWF observed in
patients with aortic stenosis associated with an increased
risk of postoperative bleeding (22,23). We speculate that in
children with CCHD, abnormal interactions of VWF with
membranes may occur at sites of altered flow conditions (for
example, either normal or surgically created systemic-to-
pulmonary connections). The lowest VWF:Ag levels in the
study were observed in the pulmonary atresia subgroup, in
which such connections are generally present. Thus, the link
between decreased preoperative ADAMTS-13 activity and
postoperative bleeding likely resulted from an ongoing
process of pathological VWF cleavage with loss of the
largest (high-molecular-weight) multimers, which are the
most active multimers in promoting platelet adhesion and
aggregation. ADAMTS-13 consumption was suggested by
the association of low ADAMTS-13 activity with low VWF
biological activity (Table 1 and Figure 2) in the presence of
defective VWF multimeric structures (Figure 1). For extra-
large VWF multimers to be observed in plasma (not the case
in this study), a more dramatic reduction of the ADAMTS-
13 activity would likely be necessary (6). The lack of a direct
correlation between VWF multimeric abnormalities and
postoperative bleeding in our patients is not surprising.
Other authors have suggested that the ADAMTS-13 activity
and the VWF antigen level are more useful for diagnosing
complications than analyzing the VWF multimer alone (6).
After a careful analysis of factors potentially associated
with postoperative bleeding, we identified three apparently
independent predictors: ADAMTS-13 activity, APTT, and
the need for cardiopulmonary bypass. We did not evaluate
other abnormalities in coagulation factors and platelet
function that may be involved in cardiopulmonary bypass
with postoperative bleeding, which may be a limitation of
the study. ADAMTS-13 cleaves VWF physiologically, but
other enzymes are also involved under pathological condi-
tions. Several enzymes promote VWF proteolysis, including
elastase and plasmin (24,25). The activity of these enzymes
may be enhanced following cardiopulmonary bypass.
Further complementary studies are required to evaluate
other enzymes.
In conclusion, we demonstrated that preoperative
abnormalities in circulating VWF and ADAMTS-13 may
be associated with an increased risk of postoperative
bleeding in children with CCHD. Low preoperative
ADAMTS-13 activity (e.g., below the mean level for the
group) appears to be predictive of significant bleeding.
Preoperative APTT and the need for cardiopulmonary
bypass were also identified as risk factors. To our knowl-
edge, this is the first study to reveal an association between
the activity of the VWF-cleaving protease and the risk of
bleeding in patients with CCHD undergoing surgery.
Further studies are required to provide a better under-
standing of the complex nature of perioperative coagulation
abnormalities.
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